lomefloxacin has been researched along with cefaclor anhydrous in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Guo, H | 1 |
| Ellison, WT; Gotfried, MH | 1 |
| Belousov, IuB; Efremenkova, OV; Komarova, VP | 1 |
2 review(s) available for lomefloxacin and cefaclor anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Isatin derivatives and their anti-bacterial activities.
Topics: Anti-Bacterial Agents; Bacteria; Humans; Isatin; Structure-Activity Relationship | 2019 |
2 trial(s) available for lomefloxacin and cefaclor anhydrous
| Article | Year |
|---|---|
Safety and efficacy of lomefloxacin versus cefaclor in the treatment of acute exacerbations of chronic bronchitis.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Cefaclor; Chronic Disease; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Quinolones; Recurrence; Single-Blind Method; Treatment Outcome | 1992 |
[Selection of antibacterial therapy for treatment of infections in elderly patients].
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Cefaclor; Cephalosporins; Ciprofloxacin; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Quinolones; Respiratory Tract Infections | 1998 |
1 other study(ies) available for lomefloxacin and cefaclor anhydrous
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |